Back to Journals » Drug Design, Development and Therapy » Volume 16

Corrigendum

Efficacy and Safety of Remimazolam Besylate versus Dexmedetomidine for Sedation in Non-Intubated Older Patients with Agitated Delirium After Orthopedic Surgery: A Randomized Controlled Trial [Corrigendum]

       

Authors Deng Y, Qin Z , Wu Q, Liu L, Yang X, Ju X, Zhang Y, Liu L

Received 8 August 2022

Accepted for publication 8 August 2022

Published 11 August 2022 Volume 2022:16 Pages 2681—2682

DOI https://doi.org/10.2147/DDDT.S385435

Download Article [PDF] 


Deng Y, Qin Z, Wu Q, et al. Drug Des Devel Ther. 2022;16:2439‒2451.

The authors have informed the journal that Remimazolam Tosilate was used in this study, not Remimazolam Besylate as indicated throughout the paper.

The authors apologize for any confusion this may have caused.


Read the original article


Creative Commons License © 2022 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]